Review Article
The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future
Table 10
Comparison of early phase studies of novel agents in relapsed and refractory Hodgkin’s lymphoma. Abbreviations: PR: partial response; CR: complete response; ORR: overall response rate; IL2-R: interleukin 2 receptor; HDAC: histone deacetylase; mTOR: mammalian target of rapamycin.
| Novel agent (author) | Target | No. of Pts | Route | Phase | PR (%) | CR (%) | ORR (%) |
| SGN30 (Forero-Torres 2009) | CD30 | 38 | IV | II | 0 | 0 | 0 | MDX060 (Ansell 2007) | CD30 | 47 | IV | I/II | 4 | 4 | 8 | SGN35 (Younes 2008) | CD30 | 44 | IV | I | 14 | 25 | 39 | SGN35 (Bartlett 2009) | CD30 | 17 | IV | I | 6 | 41 | 47 | CHT25 (Dancey 2009) | IL2-R radioimmunotherapy | 9 | IV | I | 33 | 33 | 66 | MGCD0103 (Younes 2007) | HDAC class I | 21 | Oral | II | 29 | 9 | 38 | Panobinostat (Dickinson 2009) | Pan HDAC | 13 | Oral | I/II | 54 | 0 | 54 | Panobinostat (Younes 2009) | Pan HDAC | 27 | Oral | II | 15 | 4 | 19 | Vorinostat (Kirschbaum 2007) | Pan HDAC | 25 | Oral | II | 4 | 0 | 4 | Everolimus (Johnston) | mTOR | 19 | Oral | II | 42 | 5 | 47 | Bortezomib (Younes 2006) | Proteasome | 14 | IV | II | 7 | 0 | 7 | Bortezomib (Blum 2007) | Proteasome | 30 | IV | II | 0 | 0 | 0 | Rituximab (Rehwald 2003) | CD20 | 14 | IV | II | 57 | 29 | 86 | Rituximab (Younes 2003) | CD20 | 22 | IV | II | 18 | 5 | 22 | Lenalidomide (Boll 2009) | Immunomodulator | 12 | Oral | II | 23 | 8 | 50 | Lenalidomide (Kuruvilla) | Immunomodulator | 17 | Oral | II | 47 | 6 | 53 |
|
|